APO Research
Talk to an analyst

APO RESEARCH · REPORT

Adrenoleukodystrophy Drugs

Adrenoleukodystrophy (ALD) is a rare, genetic, X-linked metabolic disorder caused by mutations in the ABCD1 gene that result in a deficiency in a peroxisomal protein called adrenoleukodystrophy protein (ALDP).

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Adrenoleukodystrophy (ALD) is a rare, genetic, X-linked metabolic disorder caused by mutations in the ABCD1 gene that result in a deficiency in a peroxisomal protein called adrenoleukodystrophy protein (ALDP).

Adrenoleukodystrophy (ALD) is a disease linked to the X chromosome. It is a result of fatty acid buildup caused by the relevant enzymes not functioning properly, which then causes damage to the myelin sheath of the nerves, resulting in seizures and hyperactivity. Other symptoms include problems with speaking, listening, and understanding verbal instructions.

There is currently no satisfactory therapeutic treatment available. Current treatments are limited, namely: Dietary therapy, Gene therapy, Hormone replacement and stem cell transplantation. Hormone replacement is standard for ALD patients demonstrating adrenal insufficiency.

Selected research

Market Structure

Global Adrenoleukodystrophy Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025181 pages

Choose your research edition.

Industry ResearchAdrenoleukodystrophy Drugs Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Adrenoleukodystrophy Drugs Industry Growth and Trends Forecast to 203298 pages · $3,450 USDMarket StructureGlobal Adrenoleukodystrophy Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Adrenoleukodystrophy Drugs Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Adrenoleukodystrophy Drugs Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

Adrenoleukodystrophy (ALD) is a rare, genetic, X-linked metabolic disorder caused by mutations in the ABCD1 gene that result in a deficiency in a peroxisomal protein called adrenoleukodystrophy protein (ALDP).

Adrenoleukodystrophy (ALD) is a disease linked to the X chromosome. It is a result of fatty acid buildup caused by the relevant enzymes not functioning properly, which then causes damage to the myelin sheath of the nerves, resulting in seizures and hyperactivity. Other symptoms include problems with speaking, listening, and understanding verbal instructions.

There is currently no satisfactory therapeutic treatment available. Current treatments are limited, namely: Dietary therapy, Gene therapy, Hormone replacement and stem cell transplantation. Hormone replacement is standard for ALD patients demonstrating adrenal insufficiency.

Read the full market overview

By region, North America has the highest share of revenue, exceeding 60 percent in 2019.

This report provides an overview of the global Adrenoleukodystrophy Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Adrenoleukodystrophy Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Adrenoleukodystrophy Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Adrenoleukodystrophy Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Adrenoleukodystrophy Drugs Segment by Company

Bluebird Bio Inc

NeuroVia, Inc.

Orpheris, Inc.

Minoryx

MedDay Pharmaceuticals

Adrenoleukodystrophy Drugs Segment by Type

Hormone Replacement

Transplant

Others

Adrenoleukodystrophy Drugs Segment by Application

Childhood Cerebral ALD

Adrenomyeloneuropathy (AMN)

Addison-only

Others

Adrenoleukodystrophy Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Adrenoleukodystrophy Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Adrenoleukodystrophy Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Adrenoleukodystrophy Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Adrenoleukodystrophy Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Adrenoleukodystrophy Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Adrenoleukodystrophy Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Adrenoleukodystrophy Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Adrenoleukodystrophy Drugs Industry Trends Table 2. Adrenoleukodystrophy Drugs Industry Drivers Table 3. Adrenoleukodystrophy Drugs Industry Opportunities and Challenges Table 4. Adrenoleukodystrophy Drugs Industry Restraints Table 5. Global Adrenoleukodystrophy Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Adrenoleukodystrophy Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Adrenoleukodystrophy Drugs Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Adrenoleukodystrophy Drugs Sales Market Share by Manufacturers Table 9. Global Adrenoleukodystrophy Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Adrenoleukodystrophy Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Adrenoleukodystrophy Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Adrenoleukodystrophy Drugs Manufacturers, Product Type & Application Table 13. Global Adrenoleukodystrophy Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Adrenoleukodystrophy Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Hormone Replacement Table 17. Major Manufacturers of Transplant Table 18. Major Manufacturers of Others Table 19. Global Adrenoleukodystrophy Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Adrenoleukodystrophy Drugs Sales by Type (2021-2026) & (K Units) Table 21. Global Adrenoleukodystrophy Drugs Sales by Type (2027-2032) & (K Units) Table 22. Global Adrenoleukodystrophy Drugs Sales Market Share by Type (2021-2026) Table 23. Global Adrenoleukodystrophy Drugs Sales Market Share by Type (2027-2032) Table 24. Global Adrenoleukodystrophy Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global Adrenoleukodystrophy Drugs Revenue by Type (2021-2026) & (K Units) Table 26. Global Adrenoleukodystrophy Drugs Revenue by Type (2027-2032) & (K Units) Table 27. Global Adrenoleukodystrophy Drugs Revenue Market Share by Type (2021-2026) Table 28. Global Adrenoleukodystrophy Drugs Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Childhood Cerebral ALD Table 30. Major Manufacturers of Adrenomyeloneuropathy (AMN) Table 31. Major Manufacturers of Addison-only Table 32. Major Manufacturers of Others Table 33. Global Adrenoleukodystrophy Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Adrenoleukodystrophy Drugs Sales by Application (2021-2026) & (K Units) Table 35. Global Adrenoleukodystrophy Drugs Sales by Application (2027-2032) & (K Units) Table 36. Global Adrenoleukodystrophy Drugs Sales Market Share by Application (2021-2026) Table 37. Global Adrenoleukodystrophy Drugs Sales Market Share by Application (2027-2032) Table 38. Global Adrenoleukodystrophy Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global Adrenoleukodystrophy Drugs Revenue by Application (2021-2026) & (K Units) Table 40. Global Adrenoleukodystrophy Drugs Revenue by Application (2027-2032) & (K Units) Table 41. Global Adrenoleukodystrophy Drugs Revenue Market Share by Application (2021-2026) Table 42. Global Adrenoleukodystrophy Drugs Revenue Market Share by Application (2027-2032) Table 43. Global Adrenoleukodystrophy Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Adrenoleukodystrophy Drugs Sales by Region (2021-2026) & (K Units) Table 45. Global Adrenoleukodystrophy Drugs Sales Market Share by Region (2021-2026) Table 46. Global Adrenoleukodystrophy Drugs Sales Forecasted by Region (2027-2032) & (K Units) Table 47. Global Adrenoleukodystrophy Drugs Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Adrenoleukodystrophy Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. North America Adrenoleukodystrophy Drugs Sales by Country (2021-2026) & (K Units) Table 50. North America Adrenoleukodystrophy Drugs Sales by Country (2027-2032) & (K Units) Table 51. Europe Adrenoleukodystrophy Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Europe Adrenoleukodystrophy Drugs Sales by Country (2021-2026) & (K Units) Table 53. Europe Adrenoleukodystrophy Drugs Sales by Country (2027-2032) & (K Units) Table 54. Asia Pacific Adrenoleukodystrophy Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Asia Pacific Adrenoleukodystrophy Drugs Sales by Country (2021-2026) & (K Units) Table 56. Asia Pacific Adrenoleukodystrophy Drugs Sales by Country (2027-2032) & (K Units) Table 57. South America, Middle East and Africa Adrenoleukodystrophy Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. South America, Middle East and Africa Adrenoleukodystrophy Drugs Sales by Country (2021-2026) & (K Units) Table 59. South America, Middle East and Africa Adrenoleukodystrophy Drugs Sales by Country (2027-2032) & (K Units) Table 60. Global Adrenoleukodystrophy Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Adrenoleukodystrophy Drugs Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Adrenoleukodystrophy Drugs Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Adrenoleukodystrophy Drugs Revenue Market Share by Region (2021-2026) Table 64. Global Adrenoleukodystrophy Drugs Revenue Market Share by Region (2027-2032) Table 65. Bluebird Bio Inc Company Information Table 66. Bluebird Bio Inc Business Overview Table 67. Bluebird Bio Inc Adrenoleukodystrophy Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Bluebird Bio Inc Adrenoleukodystrophy Drugs Product Portfolio Table 69. Bluebird Bio Inc Recent Development Table 70. NeuroVia, Inc. Company Information Table 71. NeuroVia, Inc. Business Overview Table 72. NeuroVia, Inc. Adrenoleukodystrophy Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. NeuroVia, Inc. Adrenoleukodystrophy Drugs Product Portfolio Table 74. NeuroVia, Inc. Recent Development Table 75. Orpheris, Inc. Company Information Table 76. Orpheris, Inc. Business Overview Table 77. Orpheris, Inc. Adrenoleukodystrophy Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Orpheris, Inc. Adrenoleukodystrophy Drugs Product Portfolio Table 79. Orpheris, Inc. Recent Development Table 80. Minoryx Company Information Table 81. Minoryx Business Overview Table 82. Minoryx Adrenoleukodystrophy Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Minoryx Adrenoleukodystrophy Drugs Product Portfolio Table 84. Minoryx Recent Development Table 85. MedDay Pharmaceuticals Company Information Table 86. MedDay Pharmaceuticals Business Overview Table 87. MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Product Portfolio Table 89. MedDay Pharmaceuticals Recent Development Table 90. Key Raw Materials Table 91. Raw Materials Key Suppliers Table 92. Adrenoleukodystrophy Drugs Distributors List Table 93. Adrenoleukodystrophy Drugs Customers List Table 94. Research Programs/Design for This Report Table 95. Authors List of This Report Table 96. Secondary Sources Table 97. Primary Sources List of Figures Figure 1. Adrenoleukodystrophy Drugs Product Image Figure 2. Global Adrenoleukodystrophy Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Adrenoleukodystrophy Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Adrenoleukodystrophy Drugs Sales (2021-2032) & (K Units) Figure 5. Global Adrenoleukodystrophy Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Adrenoleukodystrophy Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Hormone Replacement Image Figure 9. Transplant Image Figure 10. Others Image Figure 11. Global Adrenoleukodystrophy Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Adrenoleukodystrophy Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Adrenoleukodystrophy Drugs Sales Market Share by Type (2021-2032) Figure 14. Global Adrenoleukodystrophy Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Adrenoleukodystrophy Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Adrenoleukodystrophy Drugs Revenue Market Share by Type (2021-2032) Figure 17. Childhood Cerebral ALD Image Figure 18. Adrenomyeloneuropathy (AMN) Image Figure 19. Addison-only Image Figure 20. Others Image Figure 21. Global Adrenoleukodystrophy Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Adrenoleukodystrophy Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Adrenoleukodystrophy Drugs Sales Market Share by Application (2021-2032) Figure 24. Global Adrenoleukodystrophy Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Adrenoleukodystrophy Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Adrenoleukodystrophy Drugs Revenue Market Share by Application (2021-2032) Figure 27. North America Adrenoleukodystrophy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 28. North America Adrenoleukodystrophy Drugs Sales Market Share by Country (2021-2032) Figure 29. U.S. Adrenoleukodystrophy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Canada Adrenoleukodystrophy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Mexico Adrenoleukodystrophy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Adrenoleukodystrophy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Adrenoleukodystrophy Drugs Sales Market Share by Country (2021-2032) Figure 34. Germany Adrenoleukodystrophy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 35. France Adrenoleukodystrophy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 36. U.K. Adrenoleukodystrophy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Italy Adrenoleukodystrophy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Netherlands Adrenoleukodystrophy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Adrenoleukodystrophy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Adrenoleukodystrophy Drugs Sales Market Share by Country (2021-2032) Figure 41. China Adrenoleukodystrophy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Japan Adrenoleukodystrophy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 43. South Korea Adrenoleukodystrophy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Southeast Asia Adrenoleukodystrophy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 45. India Adrenoleukodystrophy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Australia Adrenoleukodystrophy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Adrenoleukodystrophy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Adrenoleukodystrophy Drugs Sales Market Share by Country (2021-2032) Figure 49. Brazil Adrenoleukodystrophy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South Africa Adrenoleukodystrophy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Saudi Arabia Adrenoleukodystrophy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Turkey Adrenoleukodystrophy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Argentina Adrenoleukodystrophy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 54. UAE Adrenoleukodystrophy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Egypt Adrenoleukodystrophy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Chile Adrenoleukodystrophy Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Global Adrenoleukodystrophy Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Adrenoleukodystrophy Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Adrenoleukodystrophy Drugs Revenue (2021-2032) & (US$ Million) Figure 60. North America Adrenoleukodystrophy Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Adrenoleukodystrophy Drugs Revenue (2021-2032) & (US$ Million) Figure 62. Europe Adrenoleukodystrophy Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Adrenoleukodystrophy Drugs Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Adrenoleukodystrophy Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Adrenoleukodystrophy Drugs Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Adrenoleukodystrophy Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Adrenoleukodystrophy Drugs Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Adrenoleukodystrophy Drugs Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Hormone Replacement
  • Transplant
  • Others
Applications
  • Childhood Cerebral ALD
  • Adrenomyeloneuropathy (AMN)
  • Addison-only
  • Others
Companies covered
  • Bluebird Bio Inc
  • NeuroVia, Inc.
  • Orpheris, Inc.
  • Minoryx
  • MedDay Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Adrenoleukodystrophy Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Adrenoleukodystrophy Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Adrenoleukodystrophy Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Adrenoleukodystrophy Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Adrenoleukodystrophy Drugs Market Dynamics
  1. 2.1 Adrenoleukodystrophy Drugs Industry Trends
  2. 2.2 Adrenoleukodystrophy Drugs Industry Drivers
  3. 2.3 Adrenoleukodystrophy Drugs Industry Opportunities and Challenges
  4. 2.4 Adrenoleukodystrophy Drugs Industry Restraints
3 Adrenoleukodystrophy Drugs Market by Manufacturers
  1. 3.1 Global Adrenoleukodystrophy Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Adrenoleukodystrophy Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Adrenoleukodystrophy Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Adrenoleukodystrophy Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Adrenoleukodystrophy Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Adrenoleukodystrophy Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Adrenoleukodystrophy Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Adrenoleukodystrophy Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Adrenoleukodystrophy Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Adrenoleukodystrophy Drugs Tier 1, Tier 2, and Tier 3
4 Adrenoleukodystrophy Drugs Market by Type
  1. 4.1 Adrenoleukodystrophy Drugs Type Introduction
  2. 4.1.1 Hormone Replacement
  3. 4.1.2 Transplant
  4. 4.1.3 Others
  5. 4.2 Global Adrenoleukodystrophy Drugs Sales by Type
  6. 4.2.1 Global Adrenoleukodystrophy Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Adrenoleukodystrophy Drugs Sales by Type (2021-2032)
  8. 4.2.3 Global Adrenoleukodystrophy Drugs Sales Market Share by Type (2021-2032)
  9. 4.3 Global Adrenoleukodystrophy Drugs Revenue by Type
  10. 4.3.1 Global Adrenoleukodystrophy Drugs Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Adrenoleukodystrophy Drugs Revenue by Type (2021-2032)
  12. 4.3.3 Global Adrenoleukodystrophy Drugs Revenue Market Share by Type (2021-2032)
5 Adrenoleukodystrophy Drugs Market by Application
  1. 5.1 Adrenoleukodystrophy Drugs Application Introduction
  2. 5.1.1 Childhood Cerebral ALD
  3. 5.1.2 Adrenomyeloneuropathy (AMN)
  4. 5.1.3 Addison-only
  5. 5.1.4 Others
  6. 5.2 Global Adrenoleukodystrophy Drugs Sales by Application
  7. 5.2.1 Global Adrenoleukodystrophy Drugs Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Adrenoleukodystrophy Drugs Sales by Application (2021-2032)
  9. 5.2.3 Global Adrenoleukodystrophy Drugs Sales Market Share by Application (2021-2032)
  10. 5.3 Global Adrenoleukodystrophy Drugs Revenue by Application
  11. 5.3.1 Global Adrenoleukodystrophy Drugs Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Adrenoleukodystrophy Drugs Revenue by Application (2021-2032)
  13. 5.3.3 Global Adrenoleukodystrophy Drugs Revenue Market Share by Application (2021-2032)
6 Global Adrenoleukodystrophy Drugs Sales by Region
  1. 6.1 Global Adrenoleukodystrophy Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Adrenoleukodystrophy Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Adrenoleukodystrophy Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Adrenoleukodystrophy Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Adrenoleukodystrophy Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Adrenoleukodystrophy Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Adrenoleukodystrophy Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Adrenoleukodystrophy Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Adrenoleukodystrophy Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Adrenoleukodystrophy Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Adrenoleukodystrophy Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Adrenoleukodystrophy Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Adrenoleukodystrophy Drugs Revenue by Region
  1. 7.1 Global Adrenoleukodystrophy Drugs Revenue by Region
  2. 7.1.1 Global Adrenoleukodystrophy Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Adrenoleukodystrophy Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Adrenoleukodystrophy Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Adrenoleukodystrophy Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Adrenoleukodystrophy Drugs Revenue (2021-2032)
  8. 7.2.2 North America Adrenoleukodystrophy Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Adrenoleukodystrophy Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Adrenoleukodystrophy Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Adrenoleukodystrophy Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Adrenoleukodystrophy Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Adrenoleukodystrophy Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Adrenoleukodystrophy Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Bluebird Bio Inc
  2. 8.1.1 Bluebird Bio Inc Company Information
  3. 8.1.2 Bluebird Bio Inc Business Overview
  4. 8.1.3 Bluebird Bio Inc Adrenoleukodystrophy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Bluebird Bio Inc Adrenoleukodystrophy Drugs Product Portfolio
  6. 8.1.5 Bluebird Bio Inc Recent Developments
  7. 8.2 NeuroVia, Inc.
  8. 8.2.1 NeuroVia, Inc. Company Information
  9. 8.2.2 NeuroVia, Inc. Business Overview
  10. 8.2.3 NeuroVia, Inc. Adrenoleukodystrophy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 NeuroVia, Inc. Adrenoleukodystrophy Drugs Product Portfolio
  12. 8.2.5 NeuroVia, Inc. Recent Developments
  13. 8.3 Orpheris, Inc.
  14. 8.3.1 Orpheris, Inc. Company Information
  15. 8.3.2 Orpheris, Inc. Business Overview
  16. 8.3.3 Orpheris, Inc. Adrenoleukodystrophy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Orpheris, Inc. Adrenoleukodystrophy Drugs Product Portfolio
  18. 8.3.5 Orpheris, Inc. Recent Developments
  19. 8.4 Minoryx
  20. 8.4.1 Minoryx Company Information
  21. 8.4.2 Minoryx Business Overview
  22. 8.4.3 Minoryx Adrenoleukodystrophy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Minoryx Adrenoleukodystrophy Drugs Product Portfolio
  24. 8.4.5 Minoryx Recent Developments
  25. 8.5 MedDay Pharmaceuticals
  26. 8.5.1 MedDay Pharmaceuticals Company Information
  27. 8.5.2 MedDay Pharmaceuticals Business Overview
  28. 8.5.3 MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 MedDay Pharmaceuticals Adrenoleukodystrophy Drugs Product Portfolio
  30. 8.5.5 MedDay Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Adrenoleukodystrophy Drugs Value Chain Analysis
  2. 9.1.1 Adrenoleukodystrophy Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Adrenoleukodystrophy Drugs Production Mode & Process
  6. 9.2 Adrenoleukodystrophy Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Adrenoleukodystrophy Drugs Distributors
  9. 9.2.3 Adrenoleukodystrophy Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst